Lupin Completes Acquisition of VISUfarma to Expand Ophthalmology Portfolio

Lupin Completes Acquisition of VISUfarma

Lupin Limited, a renowned global pharmaceutical company headquartered in Mumbai, India, has announced the successful completion of its acquisition of VISUfarma B.V., a leading European pharmaceutical entity specializing in ophthalmology. This significant development comes through a transaction with GHO Capital Partners LLP and marks an important stride in Lupin's strategy to enhance its specialized healthcare offerings.

The acquisition of VISUfarma is poised to greatly expand Lupin's ophthalmology portfolio, which now includes over 60 branded products. These new additions cover a diverse array of ophthalmic conditions including dryness of the eye, glaucoma, eyelid hygiene, blepharitis, retinal health, and specialized nutraceuticals. The acquisition is expected to leverage VISUfarma's strong commercial impact in key European markets such as Italy, the United Kingdom, Spain, Germany, and France. This is made possible by VISUfarma's experienced team in ophthalmology, which boasts strong local market knowledge and trusted relationships.

As the global demand for innovative eye care solutions rises, fueled by an aging population and increasing ophthalmic complications related to diabetes, Lupin is now in a superior position to meet these needs through VISUfarma’s established product line. Vinita Gupta, CEO of Lupin, remarked, “The acquisition of VISUfarma signifies a crucial milestone for Lupin, adding an impressive array of over 60 innovative ophthalmology products supported by a robust commercial infrastructure. Beyond immediate growth, this strategic acquisition diversifies our presence in Europe and accelerates the development of our specialty franchise.”

Paolo Cioccetti, the CEO of VISUfarma Italy, expressed excitement about the new partnership, stating, “We are thrilled to embark on this new chapter with Lupin. Their global expertise, vision, and commitment to ophthalmology make Lupin the ideal partner to elevate VISUfarma. Together, we are confident that we can significantly impact the advancement of eye care in Europe and beyond.”

About Lupin

Lupin Limited is a global pharmaceutical leader based in Mumbai, operating across more than 100 markets. The company specializes in a variety of pharmaceutical products, including both brand-name and generic formulations, complex generics, biotech products, and active pharmaceutical ingredients. Recognized by healthcare professionals and consumers worldwide, Lupin holds a strong position in India and the United States across multiple therapeutic areas such as respiratory diseases, cardiovascular health, diabetes, infectious diseases, gastrointestinal disorders, central nervous system conditions, and women’s health. With 15 state-of-the-art manufacturing sites and 7 global research centers, along with a dedicated workforce of over 24,000 professionals, Lupin is committed to improving patient health outcomes through its subsidiaries like Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.

For more information, visit www.lupin.com or follow Lupin on LinkedIn.

About VISUfarma

Founded in 2016 by the merging of the Italian company Visufarma SpA and the European business activities of Nicox S.A., VISUfarma is a pharmaceutical company focused on eye care. In 2025, the company generated revenue of 53 million euros in Italy, the UK, Spain, Germany, France, and select international markets. VISUfarma had previously been acquired by GHO Capital in 2016, and it continues to grow and innovate within the field of ophthalmology.